Nsaid Safety

---
name: nsaid-safety
description: NSAID comparison (meloxicam, carprofen, deracoxib, firocoxib, robenacoxib), species-specific dosing, GI ulceration risk factors, renal monitoring protocols, corticosteroid washout requirements, COX-1 vs. COX-2 selectivity.
---

# NSAID Safety

## Overview

Evidence-based NSAID selection, dosing by species, contraindication recognition, and safety monitoring protocols. Includes COX-1 vs. COX-2 selectivity comparison, renal/GI risk stratification, and drug interaction management.

## When to Use

- User prescribes NSAID or assesses drug safety for concurrent NSAID use
- User needs NSAID selection, dosing verification, or renal/GI monitoring plan
- Keywords: NSAID, meloxicam, carprofen, deracoxib, firocoxib, robenacoxib, GI ulcer, renal, COX, anti-inflammatory, contraindication, drug interaction

## NSAID Comparison Table

| Drug | Species | Dose | Route | Frequency | COX Selectivity | Comments |
|---|---|---|---|---|---|---|
| **Meloxicam** | Dog | 0.1-0.2 mg/kg | PO/IV/SC | Daily | COX-2 preferential | Longer half-life (12-18h); IV/SC option; first-line many practices |
| | Cat | 0.1 mg/kg | PO/SC/IV | Daily | COX-2 preferential | **CONTROVERSIAL dosing**: 0.3-0.5 mg/kg q48h alternative; GI risk lower than dogs at low dose; renal monitoring mandatory |
| | Rabbit | 0.6-1 mg/kg | PO/SC | BID | COX-2 preferential | Limited data; anecdotal use; monitor renal/GI closely |
| **Carprofen** | Dog | 2-4 mg/kg | PO/IV | BID-TID | COX-2 preferential (mild) | Rapid GI absorption; shorter half-life (8 hours); hepatotoxicity rare but reported |
| | Cat | 1-2 mg/kg | PO/IV | BID | COX-2 preferential (mild) | Limited feline data; less commonly used in cats; GI ulceration risk higher than meloxicam |
| **Deracoxib** | Dog | 1-2 mg/kg | PO | Daily | COX-2 selective | Food-dependent absorption (give with food); 5-7 day max acute, 30 days chronic (FDA restriction) |
| **Firocoxib** | Dog | 5 mg/kg | PO | Daily | COX-2 highly selective | Equine label (5 mg/kg); less GI ulceration than carprofen; excellent for orthopedic pain; expensive |
| | Horse | 0.1 mg/kg IV/5 mg/kg PO | PO/IV | Daily | COX-2 highly selective | Superior to phenylbutazone in some studies; longer plasma half-life |
| **Robenacoxib** | Dog/Cat | 1-2 mg/kg | SC/IV | Daily × 4-10 days | COX-2 selective | Short-term use primarily; less renal effects at short durations; expensive; limited US availability |

## COX-1 vs. COX-2 Selectivity

**COX-1 Functions**: Gastric mucosal protection (prostaglandins), platelet aggregation, renal hemodynamics, tissue homeostasis
- **Inhibition consequence**: GI ulceration, platelet dysfunction, renal perfusion reduction

**COX-2 Functions**: Inflammation, fever, pain; also renal and gastric roles in chronic settings
- **Selectivity advantage**: Lower GI ulceration risk; some renal protective effects at lower doses

**Clinical Implication**: COX-2 selective agents (meloxicam, firocoxib, deracoxib, robenacoxib) safer GI profiles than less-selective agents (carprofen) in short-term use; long-term use blunts selectivity advantage

## GI Ulceration Risk Factors

**Intrinsic Risk** (patient factors):
- Age (geriatric >7 years; puppies/kittens immature mucosa)
- Concurrent disease (inflammatory bowel disease, gastric ulcer history, neoplasia)
- Hepatic/renal disease (reduced clearance, decreased perfusion)
- Hypoproteinemia (<5.0 g/dL; reduced gastric mucosa protection)
- Dehydration (reduced gastric blood flow)
- NSAIDs increase risk 4-6× in dogs; cats lower baseline risk but elevation if predisposed

**Extrinsic Risk** (drug factors):
- High NSAID dose
- Prolonged duration (risk increases after 2-4 weeks)
- Concurrent corticosteroid use (synergistic ulceration risk; **contraindicated**)
- Concurrent anticoagulant (inhibited platelet aggregation)
- Multiple NSAIDs (avoid combining even "safer" pairs)

**Gastroduodenal Complications**:
- **Grade 1**: Gastric mucosal erythema, no erosion; asymptomatic
- **Grade 2**: Erosions <3 mm; vomiting possible
- **Grade 3-4**: Ulcers >3 mm, perforation risk; hematemesis, melena, severe pain

## Renal Monitoring Protocol

**Baseline Assessment** (before NSAID initiation):
- Serum creatinine, BUN, urine specific gravity (USG)
- Contraindicate NSAID if: Cr >1.8 mg/dL (dogs), >1.6 mg/dL (cats); pre-existing renal disease; dehydration present

**During Therapy**:
- Recheck BUN/creatinine at 7-10 days if new NSAID (acute phase kidney injury risk peaks early)
- Repeat at 2-4 weeks if continuing >2 weeks duration
- For chronic NSAIDs (months+): Check q3-6 months

**Renal NSAID Mechanism**:
- Decrease renal perfusion (COX-2 inhibition reduces renal vasodilation)
- Acute kidney injury risk in hypovolemic/dehydrated states
- Chronic risk: Progressive glomerulosclerosis with prolonged high-dose use

**Discontinuation Indications**:
- Creatinine increase >0.5 mg/dL from baseline
- BUN >40 mg/dL without other explanation
- Evidence of acute kidney injury (azotemia + clinical signs)
- Oliguria/polyuria development

## Species-Specific Dosing and Considerations

### Dogs
- **Standard dose**: Meloxicam 0.1-0.2 mg/kg daily; carprofen 2-4 mg/kg BID
- **Geriatric/renal disease**: Reduce to minimum effective dose; meloxicam 0.1 mg/kg daily preferred (less renal impact)
- **Post-operative**: Start pre-operatively (pre-emptive analgesia); continue 5-7 days minimum
- **Chronic orthopedic disease**: Long-term meloxicam acceptable with monitoring; consider adjuvant agents (gabapentin, joint supplements) to minimize NSAID requirements

### Cats
- **Meloxicam controversy**: AAHA (2017) recommends 0.1 mg/kg daily (same as dogs); some practitioners prefer 0.3-0.5 mg/kg q48h
  - **Rationale**: Feline renal physiology; lower baseline GI risk; extrarenal NSAID metabolism; palatability of sustained dosing
  - **Conservative approach**: 0.1 mg/kg daily with renal monitoring remains safest evidence-based recommendation
- **GI risk**: Cats more sensitive to severe GI ulceration than dogs despite lower overall baseline
- **Renal monitoring**: Mandatory (USG, BUN, creatinine baseline and q2-4 weeks)
- **Chronic use**: Short-term (acute pain, <2 weeks) preferred; long-term requires strong indication and close monitoring

### Rabbits/Small Mammals
- **Meloxicam**: 0.6-1 mg/kg PO/SC BID common dosing (limited species-specific data)
- **GI stasis risk**: Meloxicam may reduce appetite/motility; ensure adequate hydration and hay intake
- **Carprofen**: Anecdotal use; minimal data; generally avoided
- **Monitoring**: Renal monitoring less standardized; assess appetite, fecal output, hydration

### Horses
- **Firocoxib**: 5 mg/kg daily PO (approved label); superior to phenylbutazone (PBZ, older standard) in some pain models
- **Phenylbutazone**: Traditional (4.4 mg/kg daily max); longer-term GI ulceration risk; now second-line
- **Monitoring**: Renal dysfunction less common in horses; GI ulceration still risk
- **Maximum duration**: 30 days typically recommended (extended use controversial)

## Corticosteroid + NSAID Interaction

**Mechanism**: Corticosteroids inhibit phospholipase A2 (blocks arachidonic acid release); NSAIDs inhibit COX; combined blockade → synergistic GI ulceration

**Contraindication**: Absolute: Do NOT combine systemic corticosteroid + NSAID concurrently
- **Washout period**: Discontinue corticosteroid ≥1 week before initiating NSAID OR discontinue NSAID ≥1 week before corticosteroid

**Exception**: Topical corticosteroids (ophthalmic, dermal) + systemic NSAID generally safe (minimal systemic absorption)

**Alternative**: Use NSAID + adjuvant analgesic (gabapentin, tramadol) instead of corticosteroid if possible

## Drug Interactions and Contraindications

**NSAIDs + Anticoagulants** (warfarin, apixaban): Increased bleeding risk; avoid if possible; if necessary, use lowest NSAID dose, monitor INR closely
**NSAIDs + ACE Inhibitors** (enalapril, lisinopril): Combined renal perfusion reduction; acceptable in euvolemic patients; contraindicated if dehydrated
**NSAIDs + Diuretics**: Reduced renal perfusion; monitor renal function closely; ensure adequate hydration
**NSAIDs + Methotrexate**: Reduced MTX clearance; potential toxicity; monitor closely

**Absolute Contraindications**:
- Acute/chronic kidney disease (Cr >1.8 dogs, >1.6 cats without specialist guidance)
- Severe hepatic disease
- Active GI ulceration (confirmed or high suspicion)
- Platelet dysfunction disorders
- Concurrent corticosteroid (system non-topical)
- Hypersensitivity/allergy history

## GI Protection Strategies

**H2 Blockers** (famotidine 0.5-1 mg/kg q12h):
- Reduces gastric acid; modest ulceration prevention
- Minimal evidence for routine prophylaxis in short-term NSAID use
- Consider if: Geriatric, pre-existing GI disease, high-risk NSAID choice

**Proton Pump Inhibitors** (omeprazole 0.5-1 mg/kg q24h):
- Superior acid suppression to H2 blockers
- Limited evidence for routine prophylaxis short-term
- Consider if: High-risk patient, previous NSAID intolerance, chronic NSAID use

**Misoprostol** (2-5 mcg/kg q6-8h): Prostaglandin analog; promotes gastric mucosa protection
- Reduced diarrhea (side effect) in cats; avoid if GI dysmotility risk
- Limited practical use due to dosing frequency

**Evidence**: Routine GI protection not recommended for short-term (<2 weeks) NSAID use in low-risk patients; consider for high-risk or chronic use

## Monitoring and Patient Selection Workflow

1. **Assess renal function baseline**: Serum creatinine, BUN, USG; exclude if abnormal
2. **Assess GI risk**: History of ulceration, concurrent medications, age, dehydration status
3. **Select appropriate NSAID**: COX-2 selective (meloxicam, firocoxib) preferred over less-selective agents; meloxicam for cats with renal monitoring
4. **Verify no corticosteroid within 1 week**: Washout period essential
5. **Establish monitoring plan**: Recheck creatinine/BUN at 7-10 days if new prescription; q2-4 weeks if chronic; assess appetite/vomiting at each visit
6. **Educate owner**: Signs of GI ulceration (vomiting, melena, anorexia); signs of renal disease (polyuria, polydipsia, lethargy); importance of monitoring

## Limitations

- **Baseline renal assessment**: Many animals have subclinical renal disease (eGFR reduced despite normal creatinine); urine protein assessment (UP:C) not routine in screening
- **NSAID selectivity**: Clinical significance of COX-1 vs. COX-2 selectivity debated; all NSAIDs carry GI/renal risk at higher doses or longer duration
- **Feline meloxicam dosing**: Significant controversy; "safe" dose remains undefined; individual variation large
- **GI protection efficacy**: Limited high-quality evidence for routine prophylaxis; many protection strategies add cost without proven benefit in short-term use
- **Chronic NSAID use**: Long-term safety data limited; adjuvant agents (gabapentin, joint supplements) may reduce NSAID requirements but evidence variable
- **Referral**: Complex polypharmacy, unexplained renal elevation during NSAID therapy, or refractory pain → internist/pain specialist consideration